KZR
Kezar Life Sciences Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Market Cap: 74.9 Million
Primary Exchange: NASDAQ
Website: http://kezarlifesciences.com/
Shares Outstanding: 72.7 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.3171982351837668
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 1567 trading days
From: 2018-12-13 To: 2024-03-07
Lowest Point:
Kezar up 2% after hours on encouraging KZR-616 data
via: SeekingAlpha at 2019-06-13 12:27:35:000
Thinly traded micro cap Kezar Life Sciences (NASDAQ: KZR ) is up 2% after hours on the heels of positive data from the Phase 1b open-label dose-escalation portion of its Phase 1/2 study of KZR-616 in patients with systemic lupus erythematosus (SLE). The results were presented… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|